MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SKYE had -$62,533,243 decrease in cash & cash equivalents over the period. -$43,068,841 in free cash flow.

Cash Flow Overview

Change in Cash
-$62,533,243
Free Cash flow
-$43,068,841
Unit: Dollar
Positive Cash Flow Breakdown
    • Other current liabilities
    • Accounts payable
    • Other current assets
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchase of short-term investmen...
    • Gain from asset sale
    • Others

Cash Flow
2025-12-31
Net loss
-55,924,814
Write-down of vendor deposits
0
Depreciation and amortization
723,352
Net loss on disposal of asset
0
Stock-based compensation expense
7,767,694
Amortization of debt discount
0
Change in estimate for legal contingencies
0
Gain from asset sale
360,750
Prepaid expenses
302,928
Other current assets
-1,357,508
Other assets
0
Accounts payable
1,395,428
Accrued interest related party-Related Party
0
Accrued interest related party-Nonrelated Party
0
Accrued payroll liabilities
155,219
Other current liabilities
2,308,706
Operating lease liability
-181,944
Net cash, cash equivalents used in operating activities
-43,062,529
Proceeds from asset sales, net of legal expenses
360,750
Purchase of short-term investment
19,854,723
Purchases of property and equipment
6,312
Net cash, and cash equivalents used in investing activities
-19,500,285
Proceeds from warrant exercises
0
Purchase under employee stock purchase plan
29,571
Proceeds from option exercises
0
Net cash, and cash equivalents provided by financing activities
29,571
Net increase in cash and cash equivalents
-62,533,243
Cash, cash equivalents, beginning of year
68,415,741
Cash, cash equivalents, end of year
5,882,498
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Purchase under employeestock purchase plan$29,571 Net cash, and cashequivalents provided by...$29,571 Net increase in cashand cash...-$62,533,243 Canceled cashflow$29,571 Stock-based compensationexpense$7,767,694 Other currentliabilities$2,308,706 Accounts payable$1,395,428 Other current assets-$1,357,508 Depreciation andamortization$723,352 Accrued payrollliabilities$155,219 Proceeds from assetsales, net of legal...$360,750 Net cash, cashequivalents used in...-$43,062,529 Net cash, and cashequivalents used in...-$19,500,285 Canceled cashflow$13,707,907 Canceled cashflow$360,750 Net loss-$55,924,814 Purchase of short-terminvestment$19,854,723 Gain from asset sale$360,750 Prepaid expenses$302,928 Operating lease liability-$181,944 Purchases of property andequipment$6,312

Skye Bioscience, Inc. (SKYE)

Skye Bioscience, Inc. (SKYE)